百時美施貴寶稱一款淋巴瘤藥物已獲歐盟批准

環球市場播報

2025/03/14

　　百時美施貴寶（Bristol Myers Squibb）周五宣佈，歐盟委員會（EC）已批准Breyanzi®（利基邁侖賽）用於治療接受過兩線或以上系統治療後復發或難治性濾泡性淋巴瘤（FL）的成年患者。

　　該決定基於全球2期TRANSCEND FL試驗的結果，這是迄今為止評估CAR-T細胞療法在復發或難治性惰性非霍奇金淋巴瘤（NHL）患者中療效的最大規模臨牀試驗。

　　Breyanzi顯示出持久的臨牀效益，75.7%的患者在18個月時仍有反應，且安全性一致，未觀察到新的安全信號。

　　百時美施貴寶歐洲地區高級副總裁艾瑪·查爾斯（Emma Charles）表示：「Breyanzi在佛羅里達州之外得到額外批准，標誌着我們在向歐洲更多患者提供細胞療法變革性承諾的使命中邁出了關鍵一步。」

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：張俊 SF065

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2519389490"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519389490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519389490?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-14 23:28","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2519389490","market":"sh","top_or_hot":-1,"title":"百時美施貴寶稱一款淋巴瘤藥物已獲歐盟批准","media":"環球市場播報","content":"<html><body><div>\n<p>　　百時美<span><a href=\"https://laohu8.com/S/BMY\">施貴寶</a></span><span></span>（Bristol Myers Squibb）周五宣佈，歐盟委員會（EC）已批准Breyanzi®（利基邁侖賽）用於治療接受過兩線或以上系統治療後復發或難治性濾泡性淋巴瘤（FL）的成年患者。</p>\n<div><img src=\"https://n.sinaimg.cn/tech/transform/119/w550h369/20250314/cd2d-1d4d009374e02d0b259bc9d44d2f7fb0.png\"/><span></span></div>\n<p>　　該決定基於全球2期TRANSCEND FL試驗的結果，這是迄今為止評估CAR-T細胞療法在復發或難治性惰性非霍奇金淋巴瘤（NHL）患者中療效的最大規模臨牀試驗。</p>\n<p>　　Breyanzi顯示出持久的臨牀效益，75.7%的患者在18個月時仍有反應，且安全性一致，未觀察到新的安全信號。</p>\n<p>　　百時美施貴寶歐洲地區高級副總裁艾瑪·查爾斯（Emma Charles）表示：「Breyanzi在佛羅里達州之外得到額外批准，標誌着我們在向歐洲更多患者提供細胞療法變革性承諾的使命中邁出了關鍵一步。」</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張俊 SF065</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百時美施貴寶稱一款淋巴瘤藥物已獲歐盟批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百時美施貴寶稱一款淋巴瘤藥物已獲歐盟批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">環球市場播報</strong><span class=\"h-time small\">2025-03-14 23:28</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p>　　百時美<span><a href=\"https://laohu8.com/S/BMY\">施貴寶</a></span><span></span>（Bristol Myers Squibb）周五宣佈，歐盟委員會（EC）已批准Breyanzi®（利基邁侖賽）用於治療接受過兩線或以上系統治療後復發或難治性濾泡性淋巴瘤（FL）的成年患者。</p>\n<div><img src=\"https://n.sinaimg.cn/tech/transform/119/w550h369/20250314/cd2d-1d4d009374e02d0b259bc9d44d2f7fb0.png\"/><span></span></div>\n<p>　　該決定基於全球2期TRANSCEND FL試驗的結果，這是迄今為止評估CAR-T細胞療法在復發或難治性惰性非霍奇金淋巴瘤（NHL）患者中療效的最大規模臨牀試驗。</p>\n<p>　　Breyanzi顯示出持久的臨牀效益，75.7%的患者在18個月時仍有反應，且安全性一致，未觀察到新的安全信號。</p>\n<p>　　百時美施貴寶歐洲地區高級副總裁艾瑪·查爾斯（Emma Charles）表示：「Breyanzi在佛羅里達州之外得到額外批准，標誌着我們在向歐洲更多患者提供細胞療法變革性承諾的使命中邁出了關鍵一步。」</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：張俊 SF065</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-03-14/doc-inepryri6533396.shtml\">環球市場播報</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-03-14/doc-inepryri6533396.shtml","article_id":"2519389490","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519389490","pubTimestamp":1741966080,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"百時美施貴寶周五宣佈，歐盟委員會已批准Breyanzi用於治療接受過兩線或以上系統治療後復發或難治性濾泡性淋巴瘤的成年患者。　　Breyanzi顯示出持久的臨牀效益，75.7%的患者在18個月時仍有反應，且安全性一致，未觀察到新的安全信號。　　百時美施貴寶歐洲地區高級副總裁艾瑪·查爾斯表示：「Breyanzi在佛羅里達州之外得到額外批准，標誌着我們在向歐洲更多患者提供細胞療法變革性承諾的使命中邁出了關鍵一步。」","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK4532":"文艺复兴科技持仓","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","BK4581":"高盛持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4588":"碎股","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0237698245.USD":"富达环球地产基金A","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BMY":"施贵宝","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Bristol-Myers Squibb says a lymphoma drug has been approved by the EU","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"百時美施貴寶（Bristol Myers Squibb）周五宣佈，歐盟委員會（EC）已批准Breyanzi®（利基邁侖賽）用於治療接受過兩線或以上系統治療後復發或難治性濾泡性淋巴瘤（FL）的成年患者。\n\n　　該決定基於全球2期TRANSCEND FL試驗的結果，這是迄今為止評估CAR-T細胞療法在復發或難治性惰性非霍奇金淋巴瘤（NHL）患者中療效的最大規模臨牀試驗。\n　　Breyanzi顯示出持久的臨牀效益，75.7%的患者在18個月時仍有反應，且安全性一致，未觀察到新的安全信號。\n　　百時美施貴寶歐洲地區高級副總裁艾瑪·查爾斯（Emma Charles）表示：「Breyanzi在佛羅里達州之外得到額外批准，標誌着我們在向歐洲更多患者提供細胞療法變革性承諾的使命中邁出了關鍵一步。」\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：張俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}